Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) on October 18, 2010. The registrant is incorporated in Delaware with principal executive offices in Bothell, Washington. The report serves to disclose a material event under Regulation FD.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed is the announcement of a proposed public offering made via a press release issued on October 18, 2010. This press release is attached as Exhibit 99.1 and incorporated by reference.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release regarding the proposed public offering but does not contain detailed management commentary, financial guidance, or specific risk factors within the body of this 8-K.
- Legal Status: The registrant explicitly states that the information in this report, including the attached exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the details of the proposed public offering in the attached Exhibit 99.1 (Press Release), as the 8-K itself only announces its existence.
- Confirm the current ticker symbol and corporate name, noting the discrepancy between the metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing text ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review subsequent filings to determine if the proposed offering was completed, modified, or abandoned.